BeOne Medicines Q2 Earnings Call Highlights
Steadysingle sourceOne outlet reported this, in 2 reports over 2 days - no second voice in this corpus.
Wed, 5 August 2026Sat, 8 August 2026
What it is about
Aaron RosenbergJohn OylerAmit AgarwalXiao Dong WangDevelopment Lai WangGlobal Head Of ResearchBeone Medicines LtdSwitzerlandChinaNew Jersey, United StatesChan Henry LeeJpmorgan Chase CoBeone Medicines Company ProfileNasdaqZacks ResearchBarclaysSecurities Exchange CommissionMan GroupAmerica
Who published it, and when
original reportfirst to report
themarketsdaily.com
5 Aug, 19:05over 3 days8 Aug, 08:12
How it spread - 2 original reports
Wed, 5 August 2026
1 report- themarketsdaily.com19:05first to report
BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued to expand across approved indications and global markets. Chief Executive Officer John Oyler said the company raised its 2026 guidance for revenue and […]
Sat, 8 August 2026
1 report- themarketsdaily.com08:12
BeOne Medicines (NASDAQ:ONC – Get Free Report) had its price objective raised by stock analysts at Citizens Jmp from $396.00 to $405.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price target points to a potential upside of 16.29% from […]